Oral Drug May Work as Second-Line Therapy for Kidney Cancer

Share this content:

A new oral agent that was designed to selectively inhibit vascular endothelial growth factor (VEGF) receptors 1, 2 and 3 may benefit patients with advanced renal cell carcinoma who have failed a first-line systemic therapy. John Schieszer has the story in today's Medical Minute.
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters